cliantha research

Addressing the Challenges, Mitigating Risks and Making Complex Seamless

Phase I Capabilities

Read More

cliantha.com

USA | CANADA | EUROPE | INDIA

Overview

Phase I clinical trials are an integral step in the drug development process.

One of the most important considerations in the CRO selection process is a broad experience in Phase I trial execution. Cliantha Research has a track record of providing services from protocol designing to final study reporting. Cliantha' s strength of innovative study designing and skilled manpower, has led to successful completion of Phase I studies for given molecules.

TYPE OF STUDIES



MOLECULES

- Adalimumab 40 mg SC injection
- Alcaftadine antihistamine nasal spray (0.125%, 0.25% & 0.5%)
- Amphotericin B Liposome 50 mg IV infusion (3 mg/ kg dose)
- Bevacizumab 100 mg IV infusion (1 mg/kg dose)
- Ferric Carboxymaltose 750 mg/ 15 ml IV infusion
- Ferumoxytol 510 mg elemental iron/17 mL IV infusion
- Nor-ursodeoxycholic acid 500 mg, 1000 mg & 1500 mg tablets
- Ondansetron 100 mg/mL ER 30 mg, 70 mg & 100 mg IM & IV infusion (0.15 mg/ kg)
- Propofol 1% Injection IV infusion (900 mcg/kg)
- Recombinant Human albumin 20% IV infusion (10 gm, 20 gm & 40 gm)
- Trastuzumab 150 mg IV infusion (6 mg/kg dose)

CHALLENGES

Phase I: Highlights

Contact Cliantha today for more information about how we can enable you to make product launch decisions faster

For more information contact:
Abhishek Patel, GM-Business Development (Early Phase)
info@cliantha.com